Key Highlights
- Revolution Medicines witnessed a 20% overnight stock surge following breakthrough Phase 3 data showing daraxonrasib achieved the first-ever median survival exceeding 12 months in pancreatic cancer.
- The experimental treatment demonstrated a remarkable 60% reduction in mortality risk, extending patient survival to a median 13.2 months compared to just 6.7 months with conventional chemotherapy.
- The biotech firm has initiated a rolling New Drug Application (NDA) process with the FDA and is preparing worldwide regulatory submissions.
- Summit Therapeutics (SMMT) gained 3.6% following positive comparative data showing ivonescimab extended survival by 15% versus a rival treatment in lung cancer patients.
- The groundbreaking clinical findings were unveiled at the American Society of Clinical Oncology (ASCO) conference held in Chicago this past Sunday.
Revolution Medicines (RVMD) stock experienced a dramatic 20% surge during Sunday’s overnight session and continued climbing 7.3% to $169 in Monday’s premarket hours following the release of what industry experts are characterizing as “unprecedented” clinical trial outcomes for daraxonrasib, its investigational pancreatic cancer treatment.
Revolution Medicines, Inc., RVMD
The pivotal results emerged from the Phase 3 RASolute 302 clinical study, which was showcased during the ASCO Plenary Session and simultaneously published in The New England Journal of Medicine.
Patients administered daraxonrasib achieved a median overall survival of 13.2 months — representing nearly twice the 6.7-month median observed in participants receiving standard chemotherapy regimens. This milestone establishes daraxonrasib as the inaugural therapy in any Phase 3 investigation to extend median survival beyond the one-year threshold for previously treated metastatic pancreatic cancer.
The comprehensive 500-participant international trial evaluated the once-daily oral medication against conventional chemotherapy in individuals who had completed at least one prior treatment course.
Beyond extending life, daraxonrasib demonstrated a 60% reduction in mortality risk and significantly delayed disease advancement. The median progression-free survival reached 7.2 months for daraxonrasib recipients, substantially outperforming the 3.6-month median seen with chemotherapy.
Tumor response rates told an equally compelling story: approximately 32% of participants experienced measurable tumor shrinkage with daraxonrasib treatment, compared to only 11% in the chemotherapy arm. Notably, these advantages were consistent regardless of whether patients harbored detectable RAS mutations.
Additional Clinical Benefits Beyond Extended Survival
Participants receiving daraxonrasib maintained effective management of cancer-related pain for a median duration of 9.2 months, significantly exceeding the 3.8-month median observed with chemotherapy. Similarly, quality of life metrics remained stable for 5.7 months versus just 2.6 months in the comparison group.
The safety profile proved equally impressive. A mere 1.2% of daraxonrasib patients discontinued treatment due to adverse reactions, in stark contrast to the 11.2% discontinuation rate among chemotherapy recipients.
Raymond James analyst Sean McCutcheon characterized the overall survival findings as a “home run” and anticipates swift and widespread clinical adoption. Multiple brokerage firms have independently described the trial outcomes as “compelling.”
CEO Mark Goldsmith stated the medication “redefined treatment expectations” for this patient demographic.
Revolution Medicines has commenced a rolling NDA submission process and intends to pursue regulatory approvals from agencies worldwide, including the FDA, utilizing a Commissioner’s National Priority Voucher. The FDA has already granted authorization for an expanded access program, enabling qualified patients to obtain the treatment prior to potential formal approval.
RVMD stock has experienced nearly 100% appreciation year-to-date, with May alone contributing over 9% gains.
Summit Therapeutics Records Positive Movement
Summit Therapeutics (SMMT) advanced 3.6% to $18.17 in premarket activity following the announcement that ivonescimab — co-developed with Chinese collaborator Akeso — demonstrated a 15% survival benefit compared to Tevimbra in direct comparative testing.
Individuals with advanced squamous non-small cell lung cancer who received ivonescimab combined with chemotherapy survived an average of 27.9 months, surpassing the 23.7-month average for those treated with Tevimbra plus chemotherapy.
The investigation was executed in China. Summit maintains commercial rights to ivonescimab across the U.S., Canada, Europe, and Japan through a partnership valued at up to $5 billion.
Certain analysts expressed measured caution. Jefferies analyst Faisal Khurshid suggested investors will likely scrutinize whether these outcomes can be reproduced in international studies, especially within U.S. and European populations.
SMMT stock has remained relatively unchanged throughout the current year.
